Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.01, Zacks reports.
Contineum Therapeutics Stock Performance
Shares of NASDAQ CTNM traded down $0.15 during midday trading on Friday, reaching $18.40. The stock had a trading volume of 44,394 shares, compared to its average volume of 73,289. Contineum Therapeutics has a 12-month low of $13.27 and a 12-month high of $22.00. The stock has a 50-day moving average of $17.58 and a 200-day moving average of $17.77.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CTNM. Robert W. Baird began coverage on shares of Contineum Therapeutics in a report on Tuesday, October 22nd. They set an "outperform" rating and a $32.00 price objective for the company. Royal Bank of Canada lowered their price target on Contineum Therapeutics from $32.00 to $31.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, Baird R W raised Contineum Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Contineum Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $29.25.
Check Out Our Latest Stock Analysis on CTNM
About Contineum Therapeutics
(
Get Free Report)
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Read More
Before you consider Contineum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Contineum Therapeutics wasn't on the list.
While Contineum Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
